Scandinavian ChemoTech

Scandinavian ChemoTech AB is pleased to announce that its Animal Care division has secured a significant order for a new vetIQure™ TSE system from TeamVet Group in Germany. The order is worth 48,000 EUR and in total, sales have reached 85,000 EUR in May so far.

Equine clinic Burg Müggenhausen is one of the most renowned and innovative referral equine hospitals in Germany and part of TeamVet group. TeamVet is an independent network of selected veterinary clinics and practices in Germany, focusing on the sustainable development of their facilities. Their philosophy emphasizes autonomy and responsibility, while also networking processes and competencies. The TeamVet network includes nearly 20 clinics and practices dedicated to horses and 10 clinics for smaller companion animals.

Dr. Vanessa André is a DVM specializing in equine surgery and tumour treatments, she also holds the position as CEO at Equine Clinic Burg Müggenhausen alongside Dr. Thomas Weinberger. Dr. André and her team have spent the past three weeks evaluating the TSE therapy and have also received training and certification to use the vetIQure device.

Dr André stated, "I truly appreciate that the TSE is much less destructive than many other therapies. The system constantly provides feedback and helps the veterinarian reach the right energy level for each treatment, minimizing the risk of unwanted destruction and trauma. The fact that TSE can often be performed without general anesthesia reduces risks, speeds up the therapy, and improves health economics for equine hospitals."

"The entire company is energized to see that we can deliver significant and consistent sales growth. We are proud and delighted to begin our collaboration with the TeamVet group, DVM Vanessa André, and her team of the Equine clinic Burg Müggenhausen. Their clinical excellence and dedication to veterinary care inspire all of us at Vetiqure, and we greatly value them as partners," " said Mohan Frick, CEO of Scandinavian ChemoTech.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-05-2024 08:15 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.